Company news

Argenica Therapeutics Ltd news in 2022

Argenica Therapeutics Ltd's news releases, calls and decks from 2022, newest first.

View company

Successful Completion of Phase 1 Clinical Trial Dosing

December 20, 2022

SRC Approves Commencement Of Fourth And Final Cohort Dosing

December 7, 2022

Phase 1 Clinical Trial Progress Update

November 24, 2022

Safety Review Committee Approves Third Cohort Commencement

November 17, 2022

Sentinel Subjects Dosed in Second Cohort of Phase 1 Trial

November 6, 2022

Safety Review Committee Approves Second Cohort

November 1, 2022

No Serious Safety Issues Observed in First Cohort

October 25, 2022

First Healthy Adult Subject Dosed in Phase 1 Trial of ARG007

October 16, 2022

Argenica Receives $1.38m R&D Tax Incentive Cash Refund

October 3, 2022

Further Positive Preclinical Results for ARG-007 In HIE

September 28, 2022

Argenica Receives Ethics Approval To Commence Phase 1 Trial

September 6, 2022

Appendix 4E & Annual Report 30 June 2022

August 23, 2022

Peer Reviewed Paper Published on Preclinical Safety Study

July 6, 2022

Application for quotation of securities - AGN

June 9, 2022

Argenica Successfully Completes $5.5m Placement

June 3, 2022

Argenica Therapeutics: Proposed issue of securities - AGN

June 2, 2022

Successful Completion of Final Pre-Clinical PK Study

May 18, 2022

GLP Safety Studies Successfully Completed

May 4, 2022

Maximum Tolerated Dose Successfully Established in Studies

April 25, 2022

Argenica Appoints CEO Dr Liz Dallimore Managing Director

April 3, 2022

Positive Preclincal Data on Efficacy in New Indication

March 29, 2022

Peer Reviewed Paper Published on Preclinical Study

March 20, 2022

Successful Completion of Final GLP Genotoxicity Studies

February 23, 2022

Preliminary Pre-Clinical Tox Studies Successfully Completed

January 23, 2022

Decks in 2022